DENTAL-MONITORING
16.3.2020 19:13:09 CET | Business Wire | Press release
Dental Monitoring tele dentistry solutions allow dental professionals to connect with their patients remotely and in a HIPAA compliant manner. Our unique technology enables dentists and orthodontists to assess, monitor treatment, and communicate with their patients as much as needed, even when they are at home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005750/en/
Given the unprecedented situation we are facing worldwide, and with patient access to practices becoming more difficult, Dental Monitoring’s priorities have shifted to supporting all dental professionals whoever and wherever they are, to continue the care of their patients, as well as ensuring the continuity of their practices. Our current solutions use the full extent of our AI engine, and complete onboarding for practices can often take a few weeks to integrate fully. Therefore we have decided to refocus our company priorities to launch immediately two new “Light ” versions of our existing solutions. These new versions will be simpler and more immediate to implement for these times - rapid on-boarding and roll-out to all patients:
Photo Monitoring Light :
Simplified at-home monitoring platform with instant two-way communication with patients.
Capturing pictures of the mouth through the DM App allowing doctors to :
- Evaluate remotely their patients' current oral situation or treatment progress as if they were in the practice
- Have two way communication and guidance between doctor and patient
- Send annotated pictures directly via the patient App so patients can better understand their doctor’s guidance.
Photo Monitoring Light will also enable the clinical team to request an immediate DM scan when a patient requests immediate feedback, so that the doctor can better evaluate the patient’s situation and advise accordingly.
To implement Photo Monitoring Light: please visit https://dental-monitoring.com/maintain-patient-care/
SmileMate Virtual Consultation:
Remote assessment of new and existing patients.
All patient calls can be pre-qualified remotely using the SmileMate assessment tool directly through doctors practice websites.
The process is simple:
Step 1- The patient clicks on the widget on the doctor’s website, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an app or use cheek retractors)
Step 2- A comprehensive customized report and treatment option is automatically generated by our AI engine and sent to the doctor
Step 3- Doctors qualify the patient’s needs on their SmileMate portal
Step 4- Doctors customize and share the report with the patient with advice or a booking link.
To implement SmileMate Virtual Consultation please visit: https://dental-monitoring.com/maintain-patient-care/
Fast-Track Accelerated On-Boarding.
Photo Monitoring Light and SmileMate Virtual Consultation are ready for use in minutes after doctors and their teams have performed our free fast-track accelerated training. Implementing fast-track onboarding into dental practices is simplified through our new streamlined process, which is done 100% remotely through webinars by our customer support team.
Call us or visit: https://dental-monitoring.com/maintain-patient-care/
to book a time slot for our next training session.
Opening up a dedicated 24/7 hotline to answer any questions or needs during the pandemic.
Our priority has always been our customers and their patients. Over the next few months, we will be solely focused on delivering solutions that can help doctors maintain the expert care they provide to their patients. To that extent, and during the pandemic, we will maximize accessibility to our solutions by reducing our price on these new solutions by 50% :
- Photo Monitoring Light will be accessible for US$3 per month/patient monitored
- For SmileMate Virtual Consultation will be at US$150/month for 50 unique patient scans
We have also directed our worldwide sales force to focus 100% on Customer Service - working side by side with doctors to help treat their patients remotely.
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States, and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
